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Abstract
Background: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by excessive production of
extracellular matrix by fibroblasts on skin and internal organs. Although Th2 cells have been involved in fibroblast
stimulation, hyperactivated B cells may also play an important role. Regulatory B cells (Bregs) are cells capable of
inhibiting inflammatory responses and controlling autoimmune diseases. Although many Breg populations have in
common the ability to produce high amounts of IL-10, a unique surface marker defining most human Bregs is lacking.
It has been described in mice that T cell Ig and mucin domain protein 1 (TIM-1) is an inclusive marker for Bregs, and
that TIM-1+ B cells are able to prevent the development of autoimmunity. The aim of this work was to evaluate TIM-1
as a marker for human IL-10+ Bregs, and to determine whether TIM-1+ B cells are defective in SSc patients.
Methods: SSc patients (n = 39) and 53 healthy subjects were recruited. TIM-1 and IL-10 expression was assessed in
resting or activated peripheral blood CD19+ B cells by flow cytometry. The regulatory function of TIM-1+ or activated B
cells from SSc patients and healthy subjects was assessed in autologous and allogenic co-cultures with CD4+ T cells,
where T cell proliferation and IFN-γ, IL-17, TNF-α and IL-4 production by T cells was measured by flow cytometry.
Results: TIM-1 and IL-10 were preferentially expressed in transitional B cells, but were upregulated in naïve and memory
B cells upon stimulation. The frequency of transitional TIM-1+ IL-10+ B cells was significantly decreased in SSc patients
compared to healthy controls. In addition, activated B cells from SSc patients induced stronger allogenic Th1 and Th2
responses than activated B cells from healthy controls. Finally, TIM-1+ B cells, including transitional and non-transitional
cells, exhibited a higher CD4+ T cell suppressive ability than TIM-1− B cells in healthy controls, but not in SSc patients.
Conclusions: TIM-1 is a unique marker for the identification of a human IL-10+ Breg subpopulation which is partially
superimposed with transitional B cells. Alterations in TIM-1+ B cells could contribute to the development of autoimmune
diseases such as SSc.
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Background
B cells play a central role in immune homeostasis, not
only as precursors of antibody-secreting plasma cells, but
also by presenting antigens and activating T cells, secret-
ing a multiplicity of cytokines, and performing immune
regulatory functions [1, 2]. The maintenance of immune
tolerance and prevention of autoimmunity is exerted by
different subpopulations of regulatory B cells (Bregs),
which include type 2 marginal zone precursors [3],
CD1dhighCD5+ B10 cells [4], plasmablasts [5], and plasma
cells [6] in mice; and CD24highCD38high transitional B cells
[7], CD24highCD27+ B10 cells [8], and CD25highCD86high
B cells [9] in humans. Nearly all of them have been
functionally classified as regulatory based on their ability
to secrete interleukin (IL)-10, suppress the differentiation
or activation of pro-inflammatory immune cells, such as
monocytes, dendritic cells, CD4+ T cells, and cytotoxic
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CD8+ T cells and/or induce the differentiation or activa-
tion of regulatory T cells and invariant natural killer T
(iNKT) [10]. However, a unique marker common to most
human Breg populations has not been found so far.
Studies in mice have postulated T cell Ig and mucin do-
main protein 1 (TIM-1) as an inclusive marker for IL-10+
Bregs [11–13]. TIM-1 binds to phosphatidylserine, which
is flipped to the outer leaflet of apoptotic cell membranes,
conveying phagocytosis by macrophages and IL-10 ex-
pression by B cells [11, 14]. Adoptive transfer of TIM-1+ B
cells prevents allograft rejection and attenuates the devel-
opment of experimental autoimmune encephalomyelitis
(EAE) [12], while susceptible mice with a mutated TIM-1
molecule develop accelerated lupus [13]. Although TIM-1
+ cells have been found to be enriched in IL-10-expressing
human B cells [15–17], their regulatory function and their
association with systemic autoimmune diseases have been
insufficiently characterized.
Systemic Sclerosis (SSc) is a systemic autoimmune
disease with pathophysiological features based on three
phenomena: autoimmunity, fibrosis and vasculopathy,
which in conjunction lead to a complex pattern of mani-
festations that include an excessive deposition of extracel-
lular matrix on skin and internal organs, transient
vasoconstriction events, and the production of a wide
spectrum of autoantibodies [18]. This disease is classified
in limited cutaneous (lcSSc) and diffuse cutaneous
(dcSSc), according to the degree of skin sclerosis, internal
organ involvement, and autoantibody profile [18].
Patients with SSc have a high frequency of circulating and
skin-infiltrating type 2 CD4+ T helper cells (Th2) producing
profibrotic cytokines such as IL-4 [19, 20]. More recently,
IL-17 and IL-22-producing CD4+ T cells (Th17 and Th22,
respectively) were also found to be expanded in blood from
patients with SSc and have been related to SSc pathogenesis
[21, 22]. Furthermore, regulatory cells, such as CD4+ regula-
tory T cells (Tregs), that keep those pathogenic populations
in check, are defective in patients with SSc [23].
B cells exhibit a hyperactivated phenotype in patients with
SSc, with high expression of activation molecules and in-
flammatory cytokines [24, 25], but low expression of IL-10
[26–28]. Moreover, several reports have confirmed the bene-
fits of B cell depletion therapies on skin fibrosis and lung
function in patients with SSc [29]. However, it is not known
whether Bregs from patients with SSc are able to restrain
the activation of pro-inflammatory CD4+ Tcell responses.
Transitional B cells have been previously ascribed with
regulatory functions; however, only around 15% of them
produce IL-10 [7]. Therefore, we set out to investigate
whether TIM-1 could better identify the IL-10-producing
population amongst transitional B cells. In addition, we
investigated the presence of functional alterations in TIM-
1-expressing B cells in Th2-driven systemic autoimmune
disease with hyperactivated B cells such as SSc. Results
herein show that TIM-1 identifies most IL-10+ B cells
amongst transitional B cells. We also show that the
frequency of TIM-1+ transitional B cells, but not of other
B cell subsets, was reduced in patients with SSc compared
to healthy controls. In addition, we observed that activated
B cells from patients with SSc potentiate Th1 and Th2
responses, instead of suppressing CD4+ T cell responses as
in healthy donors. Finally, while transitional and non-
transitional TIM-1+ B cells from healthy subjects
suppressed CD4+ T cell activation, TIM-1+ B cells from
patients with SSc did not, suggesting a functional defect of
Bregs in this disease.
Methods
Patients and controls
Peripheral blood samples from 39 patients with SSc meet-
ing the American College of Rheumatology/European
League Against Rheumatism Classification Criteria for
SSc [30], and 53 healthy controls, were obtained for B cell
characterization, and purification of B and T cells. Charac-
teristics of SSc and healthy controls can be found in
Table 1. This study was approved by the Ethical Commit-
tees of the Hospital Clínico and Facultad de Medicina,
Universidad de Chile, and UCLH-National Health Service
Trust, London, UK. All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Flow cytometry and cell sorting
Dead cells were excluded from flow cytometry analysis and
cell sorting using the LIVE/DEAD® staining kit (Thermo
Fisher Scientific, Waltham, MA, USA). The following anti-
human antibodies were used for flow cytometry or cell sort-
ing: anti-CD19 FITC (clone HIB19), anti-CD24 PECy7
(clone ML5), anti-CD38 APC (clone HB-7), anti-IL-10 PE
(clone JES3-9D7), anti-TIM-1 PE (clone 1D12), anti-CD3
APC (clone SK7), anti-interferon (IFN)-γ (clone 4S.B3),
anti-IL-4 PE (clone MP4-25D2), and anti-IL-17 PerCP
(clone BL168) (BioLegend, San Diego, CA, USA). To assess
co-expression of IL-10 and TIM-1 on B cells, an anti-TIM-
1 Alexa Fluor 488 antibody (clone 219211; R&D Systems
Inc, MN, USA) was used. Intracellular cytokines were
stained using Permeabilization and IC Fixation Buffers
(eBioscience, San Diego, CA, USA). Samples were acquired
and sorted with a FACSAria III cell sorter (Becton
Dickinson, NJ, USA), and data was analyzed with the FloJo
X Software (OR, USA).
B and T cell isolation
Untouched CD19+ B cells and CD4+ T cells were isolated
from fresh heparinized whole blood or buffy coats with the
RosetteSep Human B cell or CD4+ T Cell Enrichment Cock-
tail kits, respectively (Stemcell Technologies, Vancouver,
Canada).
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B cell activation
Isolated B cells were cultured for 48 hours in RPMI 1640
medium supplemented with 10% fetal bovine serum
(HyClone, GE Healthcare, USA) at a 1 × 106 cells/ml dens-
ity, 37 °C and 5% CO2, in presence or absence of 5 μg/ml
polyclonal anti-human IgG + IgM goat antibodies (Jackson
Immunoresearch, West Grove, PA, USA) to activate the B
cell receptor (BCR) and 3 μg/ml ODN 2006 Class B CpG
oligonucleotide to activate Toll-like receptor 9 (TLR9)
(Invivogen, San Diego, CA, USA). To evaluate IL-10 se-
cretion by ELISA (Biolegend), cells were stimulated with
50 ng/ml phorbol 12-myristate 13-acetate (PMA) and
1 μg/ml ionomycin (Sigma-Aldrich, Saint Louis, MO,
USA) for the last 5 hours of culture, and for intracellular
detection of cytokines by flow cytometry, 1 μg/ml brefel-
din A (eBioscience) was simultaneously added.
CD4+ T cell and B cell co-cultures
For autologous co-cultures, total B cells and CD4+ T cells
from healthy donors were isolated. B cells were cultured for
48 hours in absence of stimulus or were stimulated with
anti-BCR antibodies plus CpG, as indicated above. Next, B
cells were harvested, washed thoroughly and plated at a 1:1
ratio with 5,6-carboxylfluorescein diacetate succinimidyl ester
(CFSE)-labeled autologous CD4+ T cells (1 × 106 total cells/
ml) and anti-CD3/anti-CD28 antibody-conjugated beads (Life
Technologies, Paisley, UK) for 5 days. To assess the regula-
tory ability of activated B cells from patients with SSc, an
allogenic assay was performed. B cells from patients with SSc
or sex-matched and age-matched healthy donors, either
unstimulated or stimulated for 48 hours, were co-cultured
for 4 days at a 1:1 ratio with CFSE-labeled CD4+ T cells from
a single healthy donor, in order to exclude the intrinsic cyto-
kine profile of CD4+ T cells from patients with SSc [21]. In
some cases, TIM-1+ and TIM-1− CD19+ B cells from patients
with SSc or healthy donors were sorted by fluorescence-
activated cell sorting, and immediately plated with
autologous CFSE-labelled CD4+ T cells at a 1:1 ratio and
anti-CD3/anti-CD28 beads for 5 days. In another experiment,
TIM-1+ CD24high CD38high transitional B cells, TIM-1−
CD24high CD38high transitional B cells and TIM-1+ CD24med/
low CD38med/low non-transitional B cells from healthy donors
were isolated by cell sorting and were cultured with autolo-
gous CD4+ CD25− T cells stimulated with 0.5 ug/ml plate-
bound anti-CD3 antibody, at a 1:2 ratio for 3 days. For all
co-cultures, 50 ng/ml PMA, 1 μg/ml ionomycin and 1 μg/ml
brefeldin A was added for the last 5 hours, and intracellular
IFN-γ, IL-4, IL-17 or TNF-α expression in CD4+ T cells was
determined by flow cytometry. An inhibition index was
calculated according to the following formula:
Inhibition index = 1 - (Percentage of cytokine-producing
CD4+ T cells in presence of B cells/Percentage of
cytokine-producing CD4+ T cells activated with anti-
CD3/anti-CD28 alone).
Statistical analyses
The two-tailed unpaired or paired Student t test was
used when appropriate to make comparisons between
two conditions or between patients with SSc and healthy
controls. Analysis of variance (ANOVA) for repeated
measures with Bonferroni post-test correction was used
for comparisons between B cell subpopulations. The
Spearman test was used to test for correlation between
continuous variables. A P value <0.05was considered
significant. All analyses were performed with GraphPad
Prism 6 (La Jolla, CA, USA).
Table 1 Main demographic and clinical characteristics of the
patients with systemic sclerosis and healthy controls
Characteristics Patients
(n = 39)
Controls
(n = 53)
Female/male, n 30/9 28/25
Age, mean ± SD 48.4 ± 11.3 40.0 ± 13.7
Disease duration, months, mean ± SD 95.4 ± 100.7
lcSSc/dcSSc, n 26/13
Rodnan score, mean ± SD 13.8 ± 6.8
Corrected DLCOa, mean ± SD 19.7 ± 6.7
ANA patternb, n (%)
Speckled 10/34 (29.4)
Nucleolar 9/34 (26.5)
Homogeneous 9/34 (26.5)
Centromere 16/34 (47.1)
Anti-Scl-70 positivity 6/33 (18.2)
Organ involvement, n (%)
Peripheral vascular 16 (41.6)
Gastrointestinal tract 27 (69.2)
Lung 21 (53.8)
Heart 16 (41.0)
Kidney 4 (10.2)
Therapy, n/total number
Prednisone 3/39
Azathioprine + prednisone 2/39
Methotrexate 4/39
D-penicillamine 1/39
Methotrexate + D-penicillamine 1/39
Methotrexate + D-penicillamine +
prednisone
1/39
Hydroxychloroquine 4/39
Methotrexate + hydroxychloroquine 1/39
Only symptomatic treatment 22/39
aMeasured in 25 patients. bSome patients have more than one pattern. SD
standard deviation, lcSSc limited cutaneous systemic sclerosis, dcSSc diffuse
cutaneous systemic sclerosis, Corrected DLCO Diffusing capacity for carbon
monoxide correction of predicted value for hemoglobin, ANA
antinuclear antibody
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Results
Patients with SSc exhibit reduced peripheral blood TIM-1
+ transitional B cells
First, the expression of TIM-1 was evaluated on different
human circulating B cell subpopulations. For this purpose,
peripheral blood mononuclear cells were isolated and
CD19+ B cell subpopulations were defined by flow cytome-
try according to the expression of CD24 and CD38 in:
CD19+ CD24high CD38high transitional B cells, CD19+
CD24med CD38med naïve B cells, CD19+ CD24high CD38med
memory B cells, and CD19+ CD24− CD38high plasmablasts,
as described elsewhere [31] (Fig. 1a). As shown in Fig. 1a,
TIM-1 was expressed in all subpopulations except plasma-
blasts. Transitional B cells exhibited a markedly higher
frequency of TIM-1-expressing cells (around 35%), com-
pared to naïve and memory cells (Fig. 1a).
Defects in different subsets of Bregs have been described
in several autoimmune diseases [7, 32]. Our group has
previously reported that compared to healthy controls,
patients with SSc, have an increased frequency of transi-
tional B cells, but a decreased proportion of IL-10-
producing transitional B cells after short stimulation with
PMA and ionomycin, and also a decreased frequency of
CD25high CD27high CD86high CD1dhigh B cells, which are
regarded as regulatory [9, 28]. To assess whether defects
in the expression of TIM-1 in B cells are associated with
the development of SSc, frequencies of TIM-1+ B cells in
peripheral blood of patients with SSc and healthy controls
were compared. Reduced frequency of B cells expressing
TIM-1 was observed exclusively in the transitional sub-
population in patients with SSc (Fig. 1b).
The hyperactivated phenotype of B cells in SSc has
been attributed to exacerbated activity of the activating
molecule CD19, and CD19 expression levels have been
found to be increased in naïve and memory B cell sub-
populations in patients with SSc [24, 33, 34]. Recently,
we have demonstrated that CD19, together with activa-
tion markers CD86 and CD40, are upregulated in transi-
tional B cells from patients with SSc [28]. Correlation
analysis was performed to find out if there is a relation-
ship between reduced expression of TIM-1 and the
hyperactivated phenotype of SSc B cells. Although there
was no significant correlation between the expression of
TIM-1 and CD86 or CD40 (data not shown), there was
direct correlation between the expression of TIM-1 and
CD19 in transitional B cells (Fig. 1c).
BCR and TLR9 activation induces an increase in TIM-1
expression that is impaired in B cells from patients with SSc
Combined stimulation of the BCR and TLR9 in human B
cells induces robust IL-10 secretion and equips them with
the ability to suppress T cell activation [35]. Therefore, the
possibility that TIM-1, as a marker of Bregs, could change
its expression after B cell activation was explored. A
significant increase in TIM-1 expression upon activation
of BCR and TLR9 was observed in all studied B cell
subpopulations except plasmablasts (Fig. 2a). Similar to
constitutive TIM-1 expression on transitional B cells, the
percentage of transitional B cells expressing TIM-1 after
activation of BCR and TLR9 was lower in patients with
SSc than in healthy controls (Fig. 2b).
Activation of B cells has been involved with lung and skin
fibrosis in a murine model of SSc [36]. Accordingly, lungs
from SSc-associated interstitial lung disease and skin
samples from patients with SSc exhibit B cell infiltration
[37, 38]. Moreover, B cell depletion therapy has shown a
beneficial effect on lung function and skin fibrosis in pa-
tients with SSc [39]. Therefore, we assessed a possible asso-
ciation between TIM-1 expression and parameters related
to lung and skin fibrosis. Interestingly, TIM-1 expression
levels on transitional B cells, either unstimulated or stimu-
lated, were higher in patients with SSc who presented with
the diffuse cutaneous form of the disease (Fig. 2c).
Moreover, there was correlation between worse respiratory
function, measured as a lower DLCO, and higher TIM-1
expression levels on stimulated transitional B cells (Fig. 2d).
Likewise, there was direct correlation between TIM-1 levels
on unstimulated or stimulated transitional B cells and the
Rodnan score, which mirrors the degree of skin fibrosis
(Fig. 2e). There was no significant association between
TIM-1 expression on B cells and the presence of autoanti-
bodies or involvement of internal organs.
A subpopulation of human transitional B cells co-express
TIM-1 and IL-10, an ability that is compromised in B cells
from patients with SSc
So far, the main common trait for all human regulatory B
cell populations is the expression of IL-10. In order to ver-
ify whether human TIM-1 is preferentially expressed on
IL-10-producing B cells, as previously shown in mice [14],
B cells were isolated and stimulated with PMA and iono-
mycin, and co-expression of surface TIM-1 and intracellu-
lar IL-10 was assessed by flow cytometry. As previously
described [7], transitional B cells were the subpopulation
most enriched in IL-10+ cells (Fig. 3a, upper panel). More
importantly, TIM-1 was expressed in the majority of
transitional IL-10+ B cells, while naïve, memor, and
plasmablast TIM-1+ B cells did not show major IL-10 ex-
pression (Fig. 3a, upper panel). Furthermore, about 60% of
transitional B cells, but also around 30% of memory B
cells, co-expressed IL-10 and TIM-1 after activation with
CpG and anti-BCR (Additional file 1: Figure S1). In
contrast, patients with SSc had significantly decreased
TIM-1+ IL-10+ transitional B cell frequencies after 5 hours
of incubation with PMA and ionomycin (Fig. 3a, lower
panel and graph). Thus, similar to murine B cells, TIM-1
was preferentially expressed in IL-10-producing B cells
from healthy donors, but not from patients with SSc.
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Fig. 1 T cell Ig and mucin domain protein 1 (TIM-1) expression by healthy and systemic sclerosis (SSc) B cell subpopulations. a Left representative dot-
plot indicating the gating strategy to identify transitional, naïve, memory, and plasmablast B cell subpopulations according to the expression of CD24
and CD38. Middle representative histograms show the expression of TIM-1 in different B cell subpopulations. Right percentage of TIM-1-expressing B
cells from healthy donors in each indicated subpopulation, n = 7. b. Representative dot-plots (left) and graph (right) show the frequency of TIM-1+ cells
on different B cell subpopulations from healthy subjects and patients with SSc. c Correlation between the expression levels of TIM-1 and CD19 in
transitional B cells from patients with SSc. FMO fluorescence minus one staining control, MFI mean fluorescence intensity. *P < 0.05, ***P < 0.001
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These differences are in line with decreased IL-10 secre-
tion by B cells stimulated with PMA/ionomycin, and a re-
duced frequency of IL-10-producing transitional B cells,
either stimulated with PMA/ionomycin alone or pre-
activated with an anti-BCR antibody and CpG, observed
in patients with SSc (Fig. 3b-c).
B cells from patients with SSc activated via BCR and TLR9
are unable to inhibit allogenic CD4+ T cell responses
B cells activated either with CpG plus anti-BCR, or with
anti-BCR alone, have been demonstrated to suppress CD4
+ T cell proliferation [40, 41]. Thus, the effect of activated
B cells expressing high levels of TIM-1 and IL-10 after
stimulation with anti-BCR plus CpG, over polyclonally
activated autologous CD4+ T cells was evaluated. Signifi-
cantly lower T cell proliferation and IFN-γ and IL-4 ex-
pression was observed in co-cultures with activated B cells
compared to unstimulated B cells, while no differences
were detected in IL-17 expression (Fig. 4a).
Thereafter, the regulatory ability of activated B cells was
compared between patients with SSc and healthy controls.
B cells from patients with SSc or healthy donors, either
unstimulated or stimulated for 48 hours with anti-BCR
plus CpG, were co-cultured with CD4+ T cells from a
single third-party healthy donor. As shown in Fig. 4b,
stimulated B cells from patients with SSc induced greater
proliferation and production of IFN-γ and IL-4 by allo-
genic CD4+ Tcells, compared to healthy controls (Fig. 4b).
These results indicate that stimulatory conditions that in-
duce B cells to upregulate TIM-1 and IL-10, and endow
them with regulatory functions, generate a Th1 and Th2
activation profile in B cells from patients with SSc.
TIM-1+ B cells from healthy subjects, but not from patients
with SSc, inhibit autologous CD4+ T cell responses
As TIM-1 defines an important population of IL-10-
producing B cells, the regulatory properties of TIM-1+ B
cells were evaluated. First, total TIM-1+ or TIM-1− B
cells from healthy subjects or patients with SSc were
isolated by cell sorting. TIM-1+ or TIM-1− B cells were
co-cultured at a 1:1 ratio with autologous CD4+ T cells,
which were stimulated with anti-CD3/anti-CD28 beads.
No differences were observed in the proliferative
response of CD4+ T cells co-cultured with TIM-1+ or
TIM-1− B cells from healthy controls; however, TIM-1+
B cells strongly suppressed the expression of pro-
inflammatory cytokines by CD4+ T cells, such as IFN-γ,
TNF-α, and IL-17, compared to TIM-1− B cells (Fig. 5a).
There was only modest inhibition of IL-4 production by
CD4+ T cells with both TIM-1+ and TIM-1− B cells
(Fig. 5a). Conversely, TIM-1+ and TIM-1− B cells from
patients with SSc did not suppress CD4+ T cell prolif-
eration or production of any of the cytokines assessed
(Fig. 5b).
Human TIM-1+ B cells and transitional B cells exhibit a
different suppressive profile
As transitional B cells have been demonstrated to sup-
press T cell activation [7], and TIM-1 is mainly expressed
on this subpopulation along with IL-10, an assay was per-
formed to address whether TIM-1+ or transitional B cells,
or both subpopulations, are responsible for the regulatory
effect previously described for transitional B cells. Three B
cell subpopulations were sorted: TIM-1+ CD24high
CD38high (TIM-1+ transitional), TIM-1− CD24high
CD38high (TIM-1− transitional), and TIM-1+ CD24med/low
CD38med/low (TIM-1+ non-transitional). The sorted cells
were co-cultured with autologous anti-CD3-activated
CD4+ CD25− T cells for 3 days, and the expression of
IFN-γ and TNF-α was assessed by flow cytometry. As
shown in Fig. 5c, although the three subpopulations
suppressed the expression of IFN-γ, both TIM-1+ subpop-
ulations tended to achieve it in a stronger way (Fig. 5c). In
contrast, on evaluation of TNF-α suppression, even
though the inhibition was modest and there was wide
inter-individual variation, TIM-1+ non-transitional cells
appeared to be more potent (Fig. 5c). These results sug-
gest that TIM-1 identifies a population of human Bregs
different from transitional B cells.
Discussion
TIM-1 is an inclusive marker for IL-10+ Bregs and an
important receptor for Breg induction and function in
mice, probably by sensing of apoptotic cells and
induction of IL-10 expression on B cells, in order to pre-
serve tolerance to self-antigens and prevent autoimmun-
ity [11, 12]. In humans, few studies have evaluated TIM-
1 expression in B cells. Liu et al. report that TIM-1 is
(See figure on previous page.)
Fig. 2 T cell Ig and mucin domain protein 1 (TIM-1) expression upon B cell receptor (BCR) and Toll-like receptor-9 (TLR9) activation in healthy subjects
and patients with systemic sclerosis (SSc). a. a Representative histograms (left) and summarizing graph (right) show the percentage of TIM-1-expressing
B cells from healthy subjects in different subpopulations, left unstimulated or activated with an anti-BCR antibody (αBCR) and CpG for 48 hours. b
Percentage of TIM-1+ total, transitional, naïve and memory B cells from healthy controls and patients with SSc after stimulation with αBCR and CpG for
48 hours. c Expression levels of TIM-1 on unstimulated (left) or stimulated (right) transitional B cells from patients with SSc with the diffuse or limited
form of the disease. d Correlation between the expression levels of TIM-1 in stimulated transitional B cells from patients with SSc and the diffusing
capacity for carbon monoxide (DLCO). e. Correlation between the expression levels of TIM-1 in unstimulated (left) or stimulated (right) transitional B
cells from patients with SSc and the Rodnan score of skin involvement. MFI mean fluorescence intensity. *P < 0.05, **P < 0.01
Aravena et al. Arthritis Research & Therapy  (2017) 19:8 Page 7 of 13
expressed in over 75% of peripheral IL-10+ B cells and
less than 25% of IL-10− B cells from healthy subjects
[15]. In contrast, Kristensen et al. found that up to 40%
of IL-10+ B cells express TIM-1, which is almost absent
from IL-10− B cells [16]. Similar to this observation, we
show that among total B cells, around 50% of PMA/
ionomycin-activated IL-10+ B cells are TIM-1+, whereas
TIM-1 is expressed in only 10% of IL-10− B cells. The
different antibody clone used to stain TIM-1 in the earl-
ier work could explain this divergence.
A
B C
Fig. 3 Co-expression of IL-10 and T cell Ig and mucin domain protein 1 (TIM-1) in B cell subpopulations from healthy subjects and patients
with systemic sclerosis (SSc). a Representative dot-plots (above) and column graph (below) show the percentage of TIM-1 and IL-10 expression on
different B cell subpopulations from healthy controls and patients with SSc stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin
for 5 hours (n = 3 patients with SSc, n = 5 healthy controls). b Levels of IL-10 secreted by total B cells from healthy controls and patients with SSc
stimulated with PMA and ionomycin alone or after incubation with an anti-B-cell receptor antibody (αBCR) and CpG for 48 hours. c. Percentage of
IL-10+ transitional B cells from healthy controls and patients with SSc stimulated under the same conditions as in b. *P < 0.05, ***P < 0.001
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It has been shown that murine TIM-1+ B cells are able to
suppress Th1 responses in vivo and promote Th2 and Treg
responses in an allograft transplantation setting [12]. Also,
TIM-1+ B cells inhibit Th1 and Th17 responses in vivo in
the EAE model [13]. In humans, TIM-1 has been used as a
surface marker to isolate Bregs and explore their in vitro
suppressive function in HIV-infected patients, demonstrat-
ing an inhibition of antigen-specific IFN-γ and TNF-α pro-
duction by CD8+ and CD4+ T cells [15]. Similarly, TIM-1+
B cells from patients with HBV-induced hepatocellular car-
cinoma do not suppress granzyme and perforin production
by CD4+ T cells [17]. To determine whether TIM-1
identifies previously described regulatory B cell subpopula-
tions, we evaluated TIM-1 expression in plasmablasts,
transitional, naïve and memory B cells. Of interest, the
transitional subpopulation, one of the better characterized
human Breg subsets, was by far the most enriched in TIM-
1+ cells, and the majority of TIM-1+ transitional B cells also
co-expressed IL-10.
In addition, we found that TIM-1+ B cells from healthy
donors have a potent suppressive capacity compared to
their TIM-1− counterparts, inhibiting the production of
Fig. 4 Modulation of CD4+ T cells by stimulated B cells from healthy controls and patients systemic sclerosis (SSc). a Representative histogram and
dot-plots (left), and graphs (right) showing the effect of B cells from a healthy control stimulated with an anti-B-cell receptor antibody (αBCR) and CpG
for 48 hours, in the proliferation (measured as percentage of 5, 6-carboxylfluorescein diacetate succinimidyl ester (CFSE)low cells) (n = 5) and in the
production of interferon (IFN)-γ (n = 7), IL-17 (n = 4) and IL-4 (n = 6) by autologous CD4+ T cells stimulated with anti-CD3 and anti-CD28 antibodies for
5 days. CD4+ T cells cultured alone (unst T) or only with stimulating antibodies (stim T) were used as negative and positive controls, respectively. b
Graphs represent the percentage of allogenic CD4+ T cells proliferating and producing IFN-γ, IL-17, and IL-4 after 4-day co-culture with B cells from
patients with SSc and healthy controls, stimulated with αBCR and CpG, or left unstimulated for 48 hours. *P < 0.05, **P < 0.01
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IFN-γ, TNF-α and IL-17 by activated CD4+ T cells. It is
noteworthy that TIM-1− transitional B cells are also able
to suppress IFN-γ production by autologous CD4+ T cells,
although not equivalently to TIM-1+ transitional B cells,
and that non-transitional TIM-1+ B cells also suppress
IFN-γ and TNF-α production, revealing that transitional B
cells and TIM-1+ B cells probably correspond to two
different, but partially superimposed, regulatory subpopu-
lations. According to previous studies, IL-10 appears to be
crucial in the inhibitory functions of TIM-1+ and transi-
tional B cells [7, 15, 17]; however, the involvement of other
mechanisms cannot be excluded.
After stimulation of BCR and TLR9 receptors, naïve
and memory B cells acquired TIM-1 expression, to-
gether with upregulation of IL-10 production. Even upon
stimulation, transitional B cells comprise the highest fre-
quency of TIM-1+ and IL-10+ cells. Such TIM-1 induc-
tion upon BCR activation was previously demonstrated
in murine germinal center B cells [42], and could be a
possible explanation for the positive correlation we ob-
served in transitional B cells from patients with SSc, be-
tween the expression levels of TIM-1 and CD19, a B cell
activating co-receptor that has been previously reported
to be upregulated in SSc B cells [28, 33]. These results
could imply a general mechanism to favor IL-10 produc-
tion by B cells in the context of an ongoing inflamma-
tory response, where an accumulation of apoptotic cells
carrying potential autoantigens and TLR ligands, bears
the inherent risk of developing autoimmunity [43].
Until now, there have been only two studies published in
which the frequency of TIM-1+ B cells has been evaluated
in autoimmune disease [16, 44]. In the first, peripheral
blood TIM-1+ IL-10+ B cells from patients with Graves’ dis-
ease and Hashimoto’s thyroiditis were found to be elevated
compared to healthy donors [16]. In contrast, in patients
with myasthenia gravis, the frequency of peripheral blood
TIM-1+ B cells was lower than in healthy controls, and was
negatively correlated with disease severity [44]. SSc is a
systemic autoimmune disease with hyperactivated B cells
having a prominent role in its pathogenicity [24, 25], and in
consequence, it is a good model for the study of Breg
frequency and function. According to our results, patients
with SSc have reduced frequencies of TIM-1+ IL-10+ B
cells, but only within the transitional subpopulation, both
in resting cells and after stimulation of the BCR and TLR9
receptor. Differences between our study and the one in
autoimmune thyroid disease may be due to the completely
disparate pathogenic mechanisms behind organ-specific
autoimmune diseases such as Graves’ disease and
Hashimoto’s thyroiditis, and a systemic disease such as SSc.
Additionally, this could also be due to the fact that no
characterization of B cell subpopulations expressing TIM-1
was performed in that study.
We also found that TIM-1 expression levels on transi-
tional B cells are higher in the diffuse form of the disease,
and that they are directly correlated with parameters re-
lated to the degree of skin and lung fibrosis and inflamma-
tion, such as the Rodnan score and DLCO, respectively.
These results are in line with our results showing upregu-
lation of TIM-1 after TLR9 and BCR activation, and with
evidence from mouse models showing increased fre-
quency of Bregs in response to inflammation [10, 45].
Our results show that TIM-1+ B cells from patients with
SSc are unable to suppress CD4+ T cell activation, and
that stimulated B cells from patients with SSc induced
stronger activation of Th1 and Th2 allogenic responses
than those from healthy controls. Two studies have
described reduced frequencies of IL-10-producing Bregs
in patients with SSc, upon stimulation with CD40L and
CpG [26], or CpG alone [27]. In the latter work, the
authors described altered activation of STAT-3 and p38
MAPK, two signaling molecules involved in IL-10 produc-
tion, after stimulation of the BCR and TLR9 receptor [27].
This evidence, together with our results, points to defect-
ive regulatory functions in Bregs from patients with SSc,
which could be partially explained by their inability to
increase TIM-1 and IL-10, and probably other inhibitory
molecules, upon stimulation, while expressing activation
molecules and pro-inflammatory cytokines, such as IL-6
[25, 28], tipping the balance toward a more pro-
inflammatory or pro-fibrotic profile. Although it has been
proposed that hyperactivated B cells directly or indirectly
help CD4+ T cells to differentiate into a Th2 profile in SSc
[29], this assumption had not been tested until now.
Conclusions
Overall, we have demonstrated that TIM-1 is a viable
marker for IL-10+ Bregs in humans and that TIM-1+ B cells
(See figure on previous page.)
Fig. 5 Suppressive function of T cell Ig and mucin domain protein 1 (TIM-1)+ B cells from healthy controls and patients with systemic sclerosis
(SSc) over T cells. a Left representative dot-plots show the effect of TIM-1+ and TIM-1− purified B cells from healthy controls in the proliferation
(measured as percentage of 5, 6-carboxylfluorescein diacetate succinimidyl ester (CFSE)low cells) and in the production of interferon (IFN)-γ, TNF-α,
IL-17, and IL-4 by autologous CD4+ T cells stimulated with anti-CD3 and anti-CD28 antibodies for 5 days. Right suppressive effect of TIM-1+ and
TIM-1− B cells from healthy donors in the proliferation and the production of IFN-γ, TNF-α, IL-17, and IL-4 by autologous stimulated CD4+ T, calcu-
lated as the inhibition index (1 – (percentage of activated CD4+ T cells in presence of B cells/percentage of activated CD4+ T cells with anti-CD3
plus anti-CD28 alone)) (n = 3). b Suppressive effect of TIM-1+ and TIM-1− B cells from patients with SSc in the proliferation, and the production of
IFN-γ, TNF-α, IL-17, and IL-4 by autologous stimulated CD4+ T, calculated as inhibition index (n = 3). c Inhibition of the expression of IFN-γ and
TNF-α by autologous activated CD4+ T cells by the indicated B cell subpopulations from healthy donors (n = 3). *P < 0.05, **P < 0.01
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are decreased in frequency and have an impaired regulatory
function in patients with SSc. The results presented herein
do not only contribute to the characterization of a novel
marker for a subpopulation of B cells with regulatory prop-
erties, but also open new routes to explore cell-based ther-
apies, given that the surface expression of TIM-1 allows the
isolation of Bregs, which could be expanded ex vivo and re-
infused to patients with autoimmune disorders such as SSc,
with the aim of replacing defective tolerance mechanisms.
Additional file
Additional file 1: Figure S1. Representative dot-plots and column graphs
showing the percentage of IL-10+ TIM-1+ in transitional, naïve, and memory B
cell subpopulations from healthy donors, left unstimulated or activated with an
anti-BCR antibody (αBCR) and CpG for 48 hours (n = 4). *P< 0.05 (PDF 583 kb)
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